

## 6. NANOMEDICINE

### 6.2. Medical Chemistry

**2.6.2.1. Impact of Ag nanoparticles on microorganisms, causative agents of purulent-inflammatory processes.** /M. Mishina, A. Syrova, V. Abramenko, V. Makarov, O. Hopta/. Georgian Medical News (GMN). – 2019. – #4. – pp. 139-143. – eng.; abs.: eng., rus., geo.

Determination of the Ag nanoparticles' impact on microorganisms causative agents of purulent-inflammatory processes was carried out It was stated that the greatest significance of growth inhibition zone was found in Staphylococcus aureus and Streptococcus pyogenes with sample length from 1 to 6 mm and Escherichia coli with 5–6 mm sample length. The investigated strains in an amount  $10^4$ – $10^6$  CFU/ml were sensitive to Ag nanoparticles activity, but at concentration 108 CFU/ml and more all strains were found persistent to samples of various length. The ability to form biofilms with planktonic cells of microorganisms under Ag nanoparticles activity sufficiently reduced from 3.4 (Candida albicans) to 5.5 (Klebsiella pneumonia) in investigated strains. The disorganization of daily biofilms was found in determining of Ag nanoparticles impact on formed biofilms of microorganisms. Fig. 7, Ref. 17.

**Keywords:** Ag nanoparticles, silver nanoparticles, antimicrobial effects, catheter-associated infections, biofilms, reference strains of microorganisms

#### References:

1. Винник Ю.С., Перьянова О.В., Онзуль Е.В., Теплякова О.В. Микробные биопленки в хирургии: механизмы образования, лекарственная устойчивость, пути решения проблемы // Новости хирургии. – Т. 8, № 6. – 2010. – С. 115–125.
2. Герхардт Ф. Методи загальної бактеріології: Пер. з англ. Т. 1 – М.: Світ, 1983. – 536 с. Режим доступу до публікації: <http://medical.co.nf>
3. Лапач С.Н., Чубенко А.В., Бабич П.Н. Статистические методы в медико-биологических исследованиях с использованием Excel. – К.: МОРИОН, 2000. – 320 с.
4. Методичні вказівки щодо застосування уніфікованих мікробіологічних (бактеріологічних) методів дослідження в клініко-діагностичних лабораторіях. Додаток I до Наказу Міністерства охорони здоров'я № 535 від 22 квітня 1985. – 123 с.
5. Мусаелян А.Г. Биопленочные инфекции //Бюллетень медицинских Интернет-конференций (ISSN 2224-610). – 2017. – Том 7. № 1. – С. 269–271.
6. Осипов В.П., Лукьянова Е.М., Антипкин Ю.Г. и др. Методика статистической обработки медицинской информации в научных исследованиях. К.: Планета людей; 2002:200.
7. Патент на корисну модель 47944 Україна, МПК G09B23/00. Спосіб відтворення біоплівки мікроорганізмів in vitro. А.Я.Циганенко, М.М.Мішина, Р.А. Курбанов(UA); Харк. націон. мед. ун-т. – № u200910353; Заявл. 12.10.2009; Опубл. 25.02.2010, Бюл. № 4.
8. Синетар Е.О., Брич О.І., Лоскутова М.М., Ткачик І.П. Антибіотикостійкість та адгезивні властивості збудників катетер-асоційованих інфекцій сечовивідних шляхів // Мікробіологічний журнал 2014; 76(3):41-46.
9. Синетар Е. О. Вплив наночастинок срібла на формування біоплівки бактеріями Enterococcus faecalis // Вісник проблем біології і медицини 2015; Вип. 4, Том 1(124):201–205.
10. Соколова Т.Н. Микробные биопленки и способы их обнаружения // Журнал Гродненского государственного медицинского университета 2014; 4:12–14.
11. Хренов П.А., Честнова Т.В. Обзор методов борьбы с микробными биопленками при воспалительных заболеваниях // Вестник новых медицинских технологий – 2013 – Том 7, № 1. Электронное издание <http://www.medsu.tula.ru/VNMT/Bulletin/E2013-1/4102.pdf>
12. Franci G., Falanga A., Galdiero S., Palomba L., Rai M., Morelli G., Galdiero M.. Silver Nanoparticles as Potential Antibacterial Agents. Molecules 2015; 20:8856–8874.
13. Kim J.S., et al. Antimicrobial effects of silver nanoparticles // Nanomedicine: Nanotechnology, Biology and Medicine 2007; 3(1):95–101.
14. Hatipoglu M.K., Keleştemur S., Altunbek M., Culha M. Source of cytotoxicity in a colloidal silver nanoparticle suspension // Nanotechnology 2015; 26(19):195- 103.
15. Rabin N., Zheng Y., Opoku–Temeng C., Du Y., Bonsu E., Sintim H.O.. Biofilm formation mechanisms and targets for developing antibiofilm agents // Future Medicinal Chemistry 2015; 7(4):493–512.

16. O'Toole G.A., Kaplan H.B., Kolter R. Biofilm formation as microbial development // *Ann. Rev. Microbiol.* 2000; 54:49–79.
17. Eckhardt S., Brunetto P.S., Gagnon J., Priebe M., Giese B., Nanobio K.M.. Silver: Its Interactions with Peptides and Bacteria, and Its Uses in Medicine // *Chemical Reviews* 2013; 113(7):4708–4754.

**2.6.2.2. Formulation of biodegradable polymeric nanoparticles containing cytotoxic substance of plant origin.** /L. Ebralidze, A. Tsertsvadze, E. Sanaia, D. Berashvili, A. Bakuridze/. *Georgian Medical News (GMN)*. – 2020. – #2. – pp. 137-142. – eng.; abs.: eng., rus., geo.

Formulation of novel drug delivery system is one of the approaches for improvement of pharmacological activity of drugs. This implies encapsulation of the API into the biocompatible polymeric material. Objective of the research was the formulation of biodegradable amino acid-based polyesteramide nanoparticles composing cytotoxic substance of plant origin. The research materials and methods included: biodegradable polyesteramide (PEA), alkaloids from *Vinca Minor*, surfactants (Tween 80, polyvinyl pirolidone, polyvinyl alcohol, Poloxamer 188). NPs size (mean particle diameter) and size distribution (polydispersity index, PDI), and zeta-potential (ZP) were measured by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, U.K.) at 25°C, UV spectrophotometer was used for %EE study. Amino acid-based PEA particles were fabricated by the modified emulsification method. Based on the studies optimal composition and fabrication condition of PEA NPs was determined. The conditions of the NPs fabrication were as follows: the O/W ratio: 1:10; the solvent: DMSO; polymer concentration in the organic phase: 50.0 mg/mL; surfactants (PVA) concentration in aqueous phase 0.5%, the stirring rate: 1000 rpm. The influence of the various factors such as organic solvents, surfactants, as well as a polymer concentration in the organic phase, surfactant concentration in the aqueous phase, the organic/water phase ratio on the NPs fabrication was studied. The NPs were characterized by size (mean particle diameter & size distribution (polydispersity index, PDI), and zeta-potential (ZP). Increase concentration of the surfactant (polyvinyl alcohol) from 0.1% to 0.5% decrease average particle size from 568±63 to 169±1.66 respectively. EE% was obtained to be around 50%. Tab. 7, Fig. 3, Ref. 8.

**Keywords:** Nanoparticle, entrapment, polymer, biodegradable, alkaloids

#### References:

1. Chen X., et al. Significant suppression of non-small-cell lung cancer by hydrophobic poly(ester amide) nanoparticles with high docetaxel loading. *Front. Pharmacol.* 2018; 9(2):1–11.
2. Crucho C.I. Synthesis of Polymeric Nanoparticles for Biomedical Delivery Applications 2015; 7.
3. Crucho C.I., Barros M.T. Polymeric nanoparticles: A study on the preparation variables and characterization methods. *Mater. Sci. Eng. C.* 2017; 80:771–784.
4. He Z., et al. Scalable fabrication of size-controlled chitosan nanoparticles for oral delivery of insulin. *Biomater.* 2017; 130:28–41.
5. Heinz H., et al. Nanoparticle decoration with surfactants: Molecular interactions, assembly, and applications. *Surf. Sci. Rep.* 2017; 72(1):1–58.
6. Hossen S., Hossain M.K., Basher M.K., Mia M.H., Rahman M.T., Uddin M.J. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. *J. Adv. Res.* 2018.
7. Rizvi S.A., Saleh A.M. Applications of nanoparticle systems in drug delivery technology. *Saudi Pharm. J.* 2018; 26(1):64–70.
8. Wurm F.R., Weiss C.K. Nanoparticles from renewable polymers. *Front. Chem.* 2014; 2:1–13.